Key result
Metformin initiation was associated with a lower risk of kidney function decline or death compared to sulfonylureas, independent of changes in BMI, blood pressure, and HbA1c.
Why the study?
Does metformin initiation reduce the risk of kidney function decline or death compared to sulfonylureas in veterans with baseline eGFR >60 mL/minute?
Cohort (n=13,238)
Yes
Does metformin initiation reduce the risk of kidney function decline or death compared to sulfonylureas in veterans with baseline eGFR >60 mL/minute?
Metformin initiation is associated with a lower risk of kidney function decline or death compared to sulfonylureas, an effect that appears independent of changes in BMI, blood pressure, and glycemic control.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for metformin preference in T2D; should not yet change practice pending randomized confirmation.
BACKGROUND AND OBJECTIVE: We recently reported that kidney function declined faster among initiators of sulfonylureas compared to metformin; however, sulfonylurea use compared to metformin use was also associated with increases in body mass index (BMI) and systolic blood pressure (SBP). We sought to determine if differences between sulfonylureas and metformin on kidney function decline were mediated by differential effects on BMI, SBP, or glucose control. METHODS: We identified 13,238 veterans who initiated sulfonylurea or metformin treatment (2000–2007) with a baseline estimated glomerular filtration rate (eGFR) >60 mL/minute, and followed them until a study event occurred, non-persistence on treatment, loss of follow-up, or end of the study. The composite outcome was a sustained decline from baseline eGFR of ≥25%, end-stage renal disease, or death. We estimated the association of cumulative measurements of potential mediators including BMI, SBP, and glycated hemoglobin on the study outcome. We determined if controlling for these time-varying covariates accounted for the differences in outcome between sulfonylurea and metformin initiators. RESULTS: Compared to sulfonylurea use, metformin use was associated with a lower risk for renal function decline or death [adjusted hazard ratio (aHR) 0.82, 95% confidence interval 0.70, 0.97]. This protective association remained significant [aHR 0.83 (0.70–0.98)] when accounting for the cumulative time-varying measurements of the three mediators of interest. CONCLUSION: Metformin initiation was associated with a lower risk of kidney function decline or death compared to sulfonylureas, which which appeared to be independent of changes in BMI, SBP, and glycated hemoglobin over time.
No takes yet. Share an insight, caveat, or question.
Hung et al. (2013) conducted a cohort in Type 2 diabetes (n=13,238). Metformin vs. Sulfonylurea was evaluated on Composite of sustained decline from baseline eGFR of ≥25%, end stage renal disease, or death (aHR 0.82, 95% CI 0.70-0.97). Metformin initiation was associated with a lower risk of kidney function decline or death compared to sulfonylureas, independent of changes in BMI, blood pressure, and HbA1c.
Synapse has enriched 10 related papers. Consider them for comparative context: